A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
NCT02944864 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53
Last updated 2024-09-23
Summary
To study the pharmacokinetic characteristics of TQ-B3395 in the human body, recommend a reasonable regimen for subsequent research.
Conditions
Interventions
- DRUG
-
TQ-B3395
TQ-B3395 p.o. qd
Sponsors & Collaborators
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-13
- Primary Completion
- 2021-05-23
- Completion
- 2022-09-15
Countries
- China
Study Locations
More Related Trials
-
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
NCT06344351 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
NCT04128085 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
NCT05213767 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
NCT04975204 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of AL2846 on Tolerance and Pharmacokinetics
NCT02779699 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
NCT06943677 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors
NCT04805060 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
NCT04144855 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
NCT05749549 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.
NCT06927349 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
NCT04275583 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
NCT04273815 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
NCT04481607 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
NCT02752516 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
NCT07291050 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
NCT03700294 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets
NCT04408079 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
NCT02939846 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
NCT04830501 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
NCT06165809 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
NCT04891653 ·Status: UNKNOWN ·Phase: PHASE1
-
3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
NCT05099536 ·Status: WITHDRAWN ·Phase: PHASE1
-
Clinical Study of BR105 Injection
NCT05351697 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
NCT01940133 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
NCT05388435 ·Status: TERMINATED ·Phase: PHASE1/PHASE2